A Phase I open-label study to evaluate the effect of multiple doses of MDV3100 (ASP9785) on the pharmacokinetics of substrates for CYP2C8, CYP2C9, CYP2C19, and CYP3A4 in patients with castration-resistant prostate cancer
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for Drug-drug interaction study with MDV3100 and a cocktail of substrates? Contact us by filling our your information to the right and we’ll respond to you.
Port Elizabeth, South Africa
George, South Africa